                         SEQUENCE LISTING

<110>  MINERVA BIOTECHNOLOGIES CORPORATION
 
<120>  STEM CELL ENHANCING THERAPEUTICS

<130>  13150-70114PCT

<160>  87    

<170>  PatentIn version 3.5

<210>  1
<211>  45
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR

<400>  1

Gly Thr Ile Asn Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys 
1               5                   10                  15      


Thr Glu Ala Ala Ser Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser Val 
            20                  25                  30          


Ser Asp Val Pro Phe Pro Phe Ser Ala Gln Ser Gly Ala 
        35                  40                  45  


<210>  2
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR related sequence

<400>  2

Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val 
1               5                   10                  15      


Val Gln Leu Thr Leu Ala Phe Arg Glu Gly 
            20                  25      


<210>  3
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR related sequence

<400>  3

Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg Tyr Asn Leu Thr 
1               5                   10                  15      


Ile Ser Asp Val Ser Val Ser Asp Val Pro Phe Pro Phe Ser Ala Gln 
            20                  25                  30          


Ser Gly Ala 
        35  


<210>  4
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR related sequence

<400>  4

Gly Thr Ile Asn Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys 
1               5                   10                  15      


Thr Glu Ala Ala Ser Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser Val 
            20                  25                  30          


Ser Asp Val 
        35  


<210>  5
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR related sequence

<400>  5

Val Val Gln Leu Thr Leu Ala Phe Arg Glu 
1               5                   10  


<210>  6
<211>  45
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR related sequence

<400>  6

Val Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His 
1               5                   10                  15      


Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg 
            20                  25                  30          


Tyr Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val 
        35                  40                  45  


<210>  7
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR related sequence

<400>  7

Ala Ser Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val 
1               5                   10                  15      


Pro Phe Pro Phe Ser Ala Gln Ser Gly Ala 
            20                  25      


<210>  8
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR related sequence

<400>  8

Asp Val Ser Val Ser Asp Val Pro Phe Pro Phe Ser Ala Gln Ser Gly 
1               5                   10                  15      


Ala 
    


<210>  9
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR related sequence

<400>  9

Val Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His 
1               5                   10                  15      


Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg 
            20                  25                  30          


Tyr Asn Leu 
        35  


<210>  10
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR related sequence

<400>  10

Gly Thr Ile Asn Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys 
1               5                   10                  15      


Thr Glu Ala Ala Ser Arg Tyr Asn Leu 
            20                  25  


<210>  11
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR related sequence

<400>  11

Gly Thr Ile Asn Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr 
1               5                   10                  15  


<210>  12
<211>  390
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  MIN-C2 Heavy chain variable region

<400>  12
gaggtccagc tggaggagtc agggggaggc ttagtgaagc ctggagggtc cctgaaactc       60

tcctgtgcag cctctggatt cactttcagt ggctatgcca tgtcttgggt tcgccagact      120

ccggagaaga ggctggagtg ggtcgcaacc attagtagtg gtggtactta tatctactat      180

ccagacagtg tgaaggggcg attcaccatc tccagagaca atgccaagaa caccctgtac      240

ctgcaaatga gcagtctgag gtctgaggac acggccatgt attactgtgc aagacttggg      300

ggggataatt actacgaata cttcgatgtc tggggcgcag ggaccacggt caccgtctcc      360

tccgccaaaa cgacaccccc atctgtctat                                       390


<210>  13
<211>  130
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 Heavy chain variable region

<400>  13

Glu Val Gln Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Leu Gly Gly Asp Asn Tyr Tyr Glu Tyr Phe Asp Val Trp Gly 
            100                 105                 110         


Ala Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser 
        115                 120                 125             


Val Tyr 
    130 


<210>  14
<211>  360
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  MIN-C2 Kappa chain variable region

<400>  14
gacattgtga tcacacagtc tacagcttcc ttaggtgtat ctctggggca gagggccacc       60

atctcatgca gggccagcaa aagtgtcagt acatctggct atagttatat gcactggtac      120

caacagagac caggacagcc acccaaactc ctcatctatc ttgcatccaa cctagaatct      180

ggggtccctg ccaggttcag tggcagtggg tctgggacag acttcaccct caacatccat      240

cctgtggagg aggaggatgc tgcaacctat tactgtcagc acagtaggga gcttccgttc      300

acgttcggag gggggaccaa gctggagata aaacgggctg atgctgcacc aactgtatcc      360


<210>  15
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 Kappa chain variable region

<400>  15

Asp Ile Val Ile Thr Gln Ser Thr Ala Ser Leu Gly Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Arg Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg 
                85                  90                  95      


Glu Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105                 110         


Ala Asp Ala Ala Pro Thr Val Ser 
        115                 120 


<210>  16
<211>  393
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  MIN-E6 Heavy chain-7 variable region

<400>  16
gaggttaagc tggaggagtc tgggggagac ttagtgaagc ctggagggtc cctgaaactc       60

tcctgtgcag cctctggatt cactttcagt agatatggca tgtcttgggt tcgccagact      120

ccagacaaga ggctggagtg ggtcgcaacc attagtagtg gtggtactta catctactat      180

ccagacagtg tgaaggggcg attcaccatc tccagagaca atgccaagaa caccctgtac      240

ctgcaaatga gcagtctgaa gtctgaggac acagccatgt attactgtgc aagggataac      300

tacggtagta gctacgacta tgctatggac tactggggtc aaggaacctc agtcaccgtc      360

tcctcagcca aaacaacagc cccatcggtc tat                                   393


<210>  17
<211>  131
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6 Heavy chain-7 variable region

<400>  17

Glu Val Lys Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Asn Tyr Gly Ser Ser Tyr Asp Tyr Ala Met Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro 
        115                 120                 125             


Ser Val Tyr 
    130     


<210>  18
<211>  456
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  MIN-E6 Heavy chain-8 variable region

<400>  18
gaggtaaagc tggaggagtc tgggggagac ttagtgaagc ctggagggtc cctgaaactc       60

tcctgtgtag tctctggatt cactttcagt agatatggca tgtcttgggt tcgccagact      120

ccaggcaaga ggctggagtg ggtcgcaacc attagtggtg gcggtactta catctactat      180

ccagacagtg tgaaggggcg attcaccatc tccagagaca atgccaagaa caccctgtac      240

ctgcaaatga gcagtctgaa gtctgaggac acagccatgt atcactgtac aagggataac      300

tacggtagga actacgacta cggtatggac tactggggtc aaggaacctc agtcaccgtc      360

tcctcagcca aaacaacagc cccatcggtc tatccactgg cccctgtgtg tggagataca      420

actggctcct cggtgactct aggatgcctg gtcaag                                456


<210>  19
<211>  152
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6 Heavy chain-8 variable region

<400>  19

Glu Val Lys Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Val Val Ser Gly Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Thr Pro Gly Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Ser Gly Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr His Cys 
                85                  90                  95      


Thr Arg Asp Asn Tyr Gly Arg Asn Tyr Asp Tyr Gly Met Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro 
        115                 120                 125             


Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser 
    130                 135                 140                 


Val Thr Leu Gly Cys Leu Val Lys 
145                 150         


<210>  20
<211>  345
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  MIN-E6 Kappa chain variable region

<400>  20
gatattgtga tcacccagac tacagcaatc atgtctgcat ctccagggga ggaggtcacc       60

ctaacctgca gtgccacctc aagtgtaagt tacatacact ggttccagca gaggccaggc      120

acttctccca aactctggat ttatagcaca tccaacctgg cttctggagt ccctgttcgc      180

ttcagtggca gtggatatgg gacctcttac tctctcacaa tcagccgaat ggaggctgaa      240

gatgctgcca cttattactg ccagcaaagg agtagttccc cattcacgtt cggctcgggg      300

acaaagttgg aaataaaacg ggctgatgct gcaccaactg tatcc                      345


<210>  21
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6 Kappa chain variable region

<400>  21

Asp Ile Val Ile Thr Gln Thr Thr Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Glu Val Thr Leu Thr Cys Ser Ala Thr Ser Ser Val Ser Tyr Ile 
            20                  25                  30          


His Trp Phe Gln Gln Arg Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 
        35                  40                  45              


Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Tyr Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Ser Pro Phe Thr 
                85                  90                  95      


Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro 
            100                 105                 110         


Thr Val Ser 
        115 


<210>  22
<211>  639
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  MIN-C2 Fab Heavy chain

<400>  22
gaggtccagc tggaggagtc tgggggaggc ttagtgaagc ctggagggtc cctgaaactc       60

tcctgtgcag cctctggatt cactttcagt ggctatgcca tgtcttgggt tcgccagact      120

ccggagaaga ggctggagtg ggtcgcaacc attagtagtg gtggtactta tatctactat      180

ccagacagtg tgaaggggcg attcaccatc tccagagaca atgccaagaa caccctgtac      240

ctgcaaatga gcagtctgag gtctgaggac acggccatgt attactgtgc aagacttggg      300

ggggataatt actacgaata cttcgatgtc tggggcgcag ggaccacggt caccgtctcc      360

tccgccaaaa cgacaccccc atctgtctat ccactggccc ctggatctgc tgcccaaact      420

aactccatgg tgaccctggg atgcctggtc aagggctatt tccctgagcc agtgacagtg      480

acctggaact ctggatccct gtccagcggt gtgcacacct tcccagctgt cctgcagtct      540

gacctctaca ctctgagcag ctcagtgact gtcccctcca gcacctggcc cagcgagacc      600

gtcacctgca acgttgccca cccagccagc aggaccgcg                             639


<210>  23
<211>  654
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  MIN-C2 Fab Kappa chain

<400>  23
gacattgtga tcacacagtc tacagcttcc ttaggtgtat ctctggggca gagggccacc       60

atctcatgca gggccagcaa aagtgtcagt acatctggct atagttatat gcactggtac      120

caacagagac caggacagcc acccaaactc ctcatctatc ttgcatccaa cctagaatct      180

ggggtccctg ccaggttcag tggcagtggg tctgggacag acttcaccct caacatccat      240

cctgtggagg aggaggatgc tgcaacctat tactgtcagc acagtaggga gcttccgttc      300

acgttcggag gggggaccaa gctggagata aaacgggctg atgctgcacc aactgtatcc      360

atcttcccac catccagtga gcagttaaca tctggaggtg cctcagtcgt gtgcttcttg      420

aacaacttct accccaaaga catcaatgtc aagtggaaga ttgatggcag tgaacgacaa      480

aatggcgtcc tgaacagttg gactgatcag gacagcaaag acagcaccta cagcatgagc      540

agcaccctca cgttgaccaa ggacgagtat gaacgacata acagctatac ctgtgaggcc      600

actcacaaga catcaacttc acccattgtc aagagcttca acaggaatga gtgt            654


<210>  24
<211>  213
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 Fab Heavy chain

<400>  24

Glu Val Gln Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Leu Gly Gly Asp Asn Tyr Tyr Glu Tyr Phe Asp Val Trp Gly 
            100                 105                 110         


Ala Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser 
        115                 120                 125             


Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val 
    130                 135                 140                 


Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val 
145                 150                 155                 160 


Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala 
                165                 170                 175     


Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro 
            180                 185                 190         


Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro 
        195                 200                 205             


Ala Ser Arg Thr Ala 
    210             


<210>  25
<211>  218
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 Fab Kappa chain

<400>  25

Asp Ile Val Ile Thr Gln Ser Thr Ala Ser Leu Gly Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Arg Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg 
                85                  90                  95      


Glu Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105                 110         


Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln 
        115                 120                 125             


Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr 
    130                 135                 140                 


Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln 
145                 150                 155                 160 


Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr 
                165                 170                 175     


Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg 
            180                 185                 190         


His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro 
        195                 200                 205             


Ile Val Lys Ser Phe Asn Arg Asn Glu Cys 
    210                 215             


<210>  26
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 light CL region amino acid sequence

<400>  26

Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu 
1               5                   10                  15      


Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe 
            20                  25                  30          


Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg 
        35                  40                  45              


Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser 
    50                  55                  60                  


Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu 
65                  70                  75                  80  


Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser 
                85                  90                  95      


Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys 
            100                 105         


<210>  27
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 heavy chain CH1 region amino acid sequence

<400>  27

Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser Ala Lys 
1               5                   10                  15      


Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln 
            20                  25                  30          


Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro 
        35                  40                  45              


Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val 
    50                  55                  60                  


His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser 
65                  70                  75                  80  


Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys 
                85                  90                  95      


Asn Val Ala His Pro Ala Ser Arg Thr Ala 
            100                 105     


<210>  28
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 light chain variable framework region 1 (FWR1) amino acid 
       sequence

<400>  28

Asp Ile Val Ile Thr Gln Ser Thr Ala Ser Leu Gly Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys 
            20              


<210>  29
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6 light chain variable framework region 1 (FWR1) amino acid 
       sequence

<400>  29

Asp Ile Val Ile Thr Gln Thr Thr Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Glu Val Thr Leu Thr Cys 
            20              


<210>  30
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 light chain variable complementarity determining region 1 
       (CDR1) amino acid sequence

<400>  30

Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His 
1               5                   10                  15  


<210>  31
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6 light chain variable complementarity determining region 1 
       (CDR1) amino acid sequence

<400>  31

Ser Ala Thr Ser Ser Val Ser Tyr Ile His 
1               5                   10  


<210>  32
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 light chain variable framework region 2 (FWR2) amino acid 
       sequence

<400>  32

Trp Tyr Gln Gln Arg Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  33
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6 light chain variable framework region 2 (FWR2) amino acid 
       sequence

<400>  33

Trp Phe Gln Gln Arg Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 
1               5                   10                  15  


<210>  34
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 light chain variable complementarity determining region 2 
       (CDR2) amino acid sequence

<400>  34

Leu Ala Ser Asn Leu Glu Ser 
1               5           


<210>  35
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6 light chain variable complementarity determining region 2 
       (CDR2) amino acid sequence

<400>  35

Ser Thr Ser Asn Leu Ala Ser 
1               5           


<210>  36
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 light chain variable framework region 3 (FWR3) amino acid 
       sequence

<400>  36

Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys 
            20                  25                  30          


<210>  37
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6 light chain variable framework region 3 (FWR3) amino acid 
       sequence

<400>  37

Gly Val Pro Val Arg Phe Ser Gly Ser Gly Tyr Gly Thr Ser Tyr Ser 
1               5                   10                  15      


Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys 
            20                  25                  30          


<210>  38
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 light chain variable complementarity determining region 3 
       (CDR3) amino acid sequence

<400>  38

Gln His Ser Arg Glu Leu Pro Phe Thr 
1               5                   


<210>  39
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6 light chain variable complementarity determining region 3 
       (CDR3) amino acid sequence

<400>  39

Gln Gln Arg Ser Ser Ser Pro Phe Thr 
1               5                   


<210>  40
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 heavy chain variable framework region 1 (FWR1) amino acid 
       sequence

<400>  40

Glu Val Gln Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 
            20                  25                  30  


<210>  41
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6-7 heavy chain variable framework region 1 (FWR1) amino 
       acid sequence

<400>  41

Glu Val Lys Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 
            20                  25                  30  


<210>  42
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6-8 heavy chain variable framework region 1 (FWR1) amino 
       acid sequence

<400>  42

Glu Val Lys Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Val Val Ser Gly Phe Thr Phe Ser 
            20                  25                  30  


<210>  43
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 heavy chain variable complementarity determining region 1 
       (CDR1) amino acid sequence

<400>  43

Gly Tyr Ala Met Ser 
1               5   


<210>  44
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6-7 heavy chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  44

Arg Tyr Gly Met Ser 
1               5   


<210>  45
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6-8 heavy chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  45

Arg Tyr Gly Met Ser 
1               5   


<210>  46
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 heavy chain variable framework region 2 (FWR2) amino acid 
       sequence

<400>  46

Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala 
1               5                   10                  


<210>  47
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6-7 heavy chain variable framework region 2 (FWR2) amino 
       acid sequence

<400>  47

Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val Ala 
1               5                   10                  


<210>  48
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6-8 heavy chain variable framework region 2 (FWR2) amino 
       acid sequence

<400>  48

Trp Val Arg Gln Thr Pro Gly Lys Arg Leu Glu Trp Val Ala 
1               5                   10                  


<210>  49
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 heavy chain variable complementarity determining region 2 
       (CDR2) amino acid sequence

<400>  49

Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  50
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6-7 heavy chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  50

Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  51
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6-8 heavy chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  51

Thr Ile Ser Gly Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  52
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 heavy chain variable framework region 3 (FWR3) amino acid 
       sequence

<400>  52

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln 
1               5                   10                  15      


Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  53
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6-7 heavy chain variable framework region 3 (FWR3) amino 
       acid sequence

<400>  53

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln 
1               5                   10                  15      


Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  54
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6-8 heavy chain variable framework region 3 (FWR3) amino 
       acid sequence

<400>  54

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln 
1               5                   10                  15      


Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr His Cys Thr Arg 
            20                  25                  30          


<210>  55
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C2 heavy chain variable complementarity determining region 3 
       (CDR3) amino acid sequence

<400>  55

Leu Gly Gly Asp Asn Tyr Tyr Glu Tyr 
1               5                   


<210>  56
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6-7 heavy chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  56

Asp Asn Tyr Gly Ser Ser Tyr Asp Tyr Ala 
1               5                   10  


<210>  57
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-E6-8 heavy chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  57

Asp Asn Tyr Gly Arg Asn Tyr Asp Tyr Gly 
1               5                   10  


<210>  58
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IGHV3 (name from Igblast): FWR1: Human IgG antibody framework 
       region sequence with 84.7% homology (249/294) to variable heavy 
       chain region of MIN-C2

<400>  58

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 
            20                  25                  30  


<210>  59
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IGHV3 (name from Igblast): FWR2: Human IgG antibody framework 
       region sequence with 84.7% homology (249/294) to variable heavy 
       chain region of MIN-C2

<400>  59

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser 
1               5                   10                  


<210>  60
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IGHV3 (name from Igblast): FWR3: Human IgG antibody framework 
       region sequence with 84.7% homology (249/294) to variable heavy 
       chain region of MIN-C2

<400>  60

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln 
1               5                   10                  15      


Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val 
            20                  25          


<210>  61
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IGkV7 (name from Igblast): FWR1: Human IgG antibody framework 
       region sequence with 76.4% homology (226/296) to variable light 
       chain region of MIN-C2

<400>  61

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Thr Cys 
            20              


<210>  62
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IGkV7 (name from Igblast): FWR2: Human IgG antibody framework 
       region sequence with 76.4% homology (226/296) to variable light 
       chain region of MIN-C2

<400>  62

Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  63
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IGkV7 (name from Igblast): FWR 3: Human IgG antibody framework 
       region sequence with 76.4% homology (226/296) to variable light 
       chain region of MIN-C2

<400>  63

Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Thr Ala Asn Tyr Tyr 
            20                  25                  30      


<210>  64
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IGHV3 (name from Igblast): FWR1: Human IgG antibody framework 
       region sequence with 84.1% homology (249/296) to variable heavy 
       chain region of MIN-E6

<400>  64

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 
            20                  25                  30  


<210>  65
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IGHV3 (name from Igblast): FWR2: Human IgG antibody framework 
       region sequence with 84.1% homology (249/296) to variable heavy 
       chain region of MIN-E6

<400>  65

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser 
1               5                   10                  


<210>  66
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IGHV3 (name from Igblast): FWR3: Human IgG antibody framework 
       region sequence with 84.1% homology (249/296) to variable heavy 
       chain region of MIN-E6

<400>  66

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln 
1               5                   10                  15      


Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  67
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IGkV3 (name from Igblast): FWR1: Human IgG antibody framework 
       region sequence with 69.5% homology (187/269) to variable light 
       chain region of MIN-E6

<400>  67

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys 
            20              


<210>  68
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IGkV3 (name from Igblast): FWR2: Human IgG antibody framework 
       region sequence with 69.5% homology (187/269) to variable light 
       chain region of MIN-E6

<400>  68

Trp Phe Gln Gln Arg Pro Gly Thr Ser Pro Lys Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  69
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IGkV3 (name from Igblast): FWR3: Human IgG antibody framework 
       region sequence with 69.5% homology (187/269) to variable light 
       chain region of MIN-E6

<400>  69

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys 
            20                  25                  30          


<210>  70
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  2D6C3 Kappa Chain Variable Region

<400>  70

Cys Asp Arg Arg Ser Ser Gln Thr Ile Val His Ser Asn Gly Asn Thr 
1               5                   10                  15      


Tyr Leu Glu 
            


<210>  71
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  2D6C3 Kappa Chain Variable Region

<400>  71

Cys Asp Arg Lys Val Ser Asn Arg Phe Ser 
1               5                   10  


<210>  72
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  2D6C3 Kappa Chain Variable Region

<400>  72

Cys Asp Arg Phe Gln Gly Ser His Val Pro Phe Thr 
1               5                   10          


<210>  73
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  2D6C3 Heavy Chain Variable Region

<400>  73

Cys Asp Arg Gly Tyr Ala Met Ser 
1               5               


<210>  74
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  2D6C3 Heavy Chain Variable Region

<400>  74

Cys Asp Arg Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp 
1               5                   10                  15      


Ser Val Lys Gly 
            20  


<210>  75
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  2D6C3 Heavy Chain Variable Region

<400>  75

Cys Asp Arg Leu Gly Gly Asp Asn Tyr Tyr Glu Tyr 
1               5                   10          


<210>  76
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  2D6C8 Kappa Chain Variable Region

<400>  76

Cys Asp Arg Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr 
1               5                   10                  15      


Met His 
        


<210>  77
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  2D6C8 Kappa Chain Variable Region

<400>  77

Cys Asp Arg Leu Val Ser Asn Leu Glu Ser 
1               5                   10  


<210>  78
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  2D6C8 Kappa Chain Variable Region

<400>  78

Cys Asp Arg Gln His Ile Arg Glu Leu Thr Arg Ser Glu 
1               5                   10              


<210>  79
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  2D6C8 Heavy Chain Variable Region

<400>  79

Cys Asp Arg Gly Tyr Ala Met Ser 
1               5               


<210>  80
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  2D6C8 Heavy Chain Variable Region

<400>  80

Cys Asp Arg Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp 
1               5                   10                  15      


Ser Val Lys Gly 
            20  


<210>  81
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  2D6C8 Heavy Chain Variable Region

<400>  81

Cys Asp Arg Leu Gly Gly Asp Asn Tyr Tyr Glu Tyr 
1               5                   10          


<210>  82
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  3C2B1 Kappa Chain Variable Region

<400>  82

Cys Asp Arg Arg Ala Ser Lys Ser Ile Ser Thr Ser Asp Tyr Asn Tyr 
1               5                   10                  15      


Ile His 
        


<210>  83
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  3C2B1 Kappa Chain Variable Region

<400>  83

Cys Asp Arg Leu Ala Ser Asn Leu Glu Ser 
1               5                   10  


<210>  84
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  3C2B1 Kappa Chain Variable Region

<400>  84

Cys Asp Arg Gln His Ser Arg Glu Leu Pro Leu Thr Phe 
1               5                   10              


<210>  85
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  3C2B1 Heavy Chain Variable Region

<400>  85

Cys Asp Arg Thr Tyr Thr Met Ser 
1               5               


<210>  86
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  3C2B1 Heavy Chain Variable Region

<400>  86

Cys Asp Arg Thr Ile Ser Thr Gly Gly Asp Lys Thr Tyr Tyr Ser Asp 
1               5                   10                  15      


Ser Val Lys Gly 
            20  


<210>  87
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  3C2B1 Heavy Chain Variable Region

<400>  87

Cys Asp Arg Gly Thr Thr Ala Met Tyr Tyr Tyr Ala Met 
1               5                   10              


